Welcome to our dedicated page for Aspira Women`s Health SEC filings (Ticker: AWH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aspira Women’s Health Inc. (AWH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on material events. These documents help investors understand changes in leadership, compensation arrangements, capital structure, and other significant developments at a women’s health diagnostics company focused on noninvasive, AI-powered tests for gynecologic diseases.
Among the filings, Form 8-K current reports are particularly relevant. For example, Aspira has filed 8-Ks describing Board decisions and executive appointments, such as the appointment of a new director with extensive experience advising laboratories and healthcare providers, and the engagement of a Chief Financial Officer under a consulting agreement that outlines salary, bonus eligibility, stock option grants, vesting schedules, and severance terms. These filings also address potential change-of-control scenarios and related option vesting provisions.
Investors can use Aspira’s SEC filings alongside its press releases to track how governance and compensation structures align with the company’s focus on AI-enabled diagnostic tests like OvaSuiteSM and its ENDOinform™ development program. While this page emphasizes current reports such as Form 8-K, it also links to other available filings that detail financial reporting, capital markets activities, and risk disclosures.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly identify items such as executive transitions, consulting agreements, and exhibit references. Real-time updates from EDGAR mean that new AWH filings, including future 10-K annual reports, 10-Q quarterly reports, or Form 4 insider transaction reports when available, can be reviewed promptly with contextual explanations.
Aspira Women's Health Inc. insider grant: Chief Financial Officer Brian Hungerford was granted an employee stock option to buy 100,000 shares of common stock at an exercise price of $0.41 per share. The option was granted and deemed executed on 09/02/2025, is exercisable beginning that date, and expires on 09/02/2035. Following the grant, Hungerford directly beneficially owns 100,000 option shares. The filing explains that 25,000 shares vest on 09/02/2026 and the remainder vests in equal monthly installments over the subsequent 36 months. The form is signed 09/04/2025.
Aspira Women's Health Inc. Form 3 filed by Brian Hungerford, who is identified as Chief Financial Officer and a director, reports that no securities are beneficially owned by the reporting person as of the event date 09/02/2025. The filing is an initial statement of beneficial ownership under Section 16 and is signed by Mr. Hungerford on 09/04/2025. The form discloses the filer’s title and address and states that no non-derivative or derivative securities are owned.
Aspira Women’s Health Inc. appointed Brian Hungerford as its new Chief Financial Officer and Principal Accounting Officer, effective September 2, 2025, under a Master Service Agreement and Statement of Work that replace former CFO Julie Carrillo.
Hungerford, who previously served as CFO of Kiromic Biopharma, will receive a $300,000 annual salary paid semi-monthly and will be eligible for a 35% cash bonus based on performance goals set by management and the board.
He is also eligible for stock options for 100,000 shares, with 25% vesting on September 2, 2026 and the remainder vesting monthly over the following 36 months. If he is terminated without cause after six months but within one year of the effective date, he is entitled to three months of continued base salary; if terminated without cause after one year, he is entitled to six months of salary. If his employment is terminated without cause or for good reason within 12 months after a change of control, all unvested options previously granted will fully vest at termination.
FAQ
What is the current stock price of Aspira Women`s Health (AWH)?
What is the market cap of Aspira Women`s Health (AWH)?
